CurifyLabs, a Finnish health technology company specializing in automated pharmaceutical compounding, has raised €12 million in Series A funding to accelerate its international expansion and product development efforts.
The funding round was led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.), Lifeline Ventures, and existing customers and employees in the United States. The investment represents a significant milestone for the company, which was founded in 2021 and has already established operations across multiple continents.
Expansion and Product Development
CurifyLabs plans to deploy the new capital to strengthen its presence in the United States, enhance supply chain capabilities, and expand customer support infrastructure. The company will also accelerate development of its PharmaPrinter Aurum, an advanced pharmaceutical compounding platform designed to automate the preparation of personalized medications.
Currently, CurifyLabs’ technology is operational in pharmacies across 21 US states as well as in European markets, positioning the company at an interesting inflection point in its growth trajectory. The involvement of existing US customers and employees in this funding round underscores confidence in the company’s market approach and execution capabilities.
According to Charlotta Topelius, Founder and CEO of CurifyLabs, the backing reflects broader confidence in the company’s vision. “This investment reflects the conviction our partners have in what we’re building,” Topelius stated. “We have set a high bar for clinical rigour, product quality and customer support, and this funding gives us the resources to raise that bar further.”
Market Context
The investment comes as European healthtech companies increasingly pursue transatlantic growth strategies, recognizing the substantial opportunities in both markets. The pharmaceutical automation and personalized medicine sectors have attracted particular investor attention, driven by the healthcare industry’s ongoing digital transformation and the growing demand for precision medicine solutions.
CurifyLabs’ focus on automating pharmaceutical compounding addresses a genuine operational challenge faced by pharmacies and healthcare systems seeking to improve efficiency while maintaining quality standards. The company’s dual-market presence suggests it has developed solutions with cross-border applicability, a factor likely considered by its investor syndicate.
The Finnish startup’s trajectory reflects the broader strength of the Nordic healthtech ecosystem, which has established itself as a significant contributor to European innovation in life sciences and healthcare technology. With this Series A capital in place, CurifyLabs joins a growing cohort of European companies scaling beyond their home markets to compete on an international stage, particularly targeting the substantial US healthcare market.